Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2023-07-12 Transaction in Own Shar…
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
Transaction in Own Shares Classification · 98% confidence The document is titled "GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial" (GENFIT: Semi-annual statement of the liquidity contract entered into with Crédit Industriel et Commercial). It explicitly reports on the status of a liquidity contract (a form of share repurchase/stabilization activity) as of June 30, 2023, detailing the number of shares and cash held, and the transactions (purchases and sales) executed during the first semester of 2023. This activity directly relates to the company managing its own shares in the market. The most appropriate category is 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities. It is not a general earnings release (ER), interim report (IR), or annual report (10-K).
2023-07-12 French
Ipsen et GENFIT annoncent les résultats positifs de l'essai de Phase III ELATIVE® évaluant elafibranor chez des patients atteints de cholangite biliaire primitive, une maladie cholestatique rare du fo
Regulatory Filings Classification · 95% confidence The document is a press release jointly issued by Ipsen and GENFIT on June 30, 2023, announcing positive Phase III trial results (ELATIVE®) for the drug elafibranor in treating Primary Biliary Cholangitis (PBC). It details efficacy data, safety profiles, and future regulatory submission intentions (FDA and EMA). This content strongly aligns with an announcement of clinical trial results and subsequent business/regulatory plans, which is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of clinical trial outcomes and future regulatory steps, and not a formal quarterly/annual financial report (10-K or IR), nor a transcript (CT), the most fitting category is Earnings Release (ER) as it communicates key performance/development milestones, or RNS as a general regulatory announcement. Given the focus on clinical trial success and immediate regulatory intent, ER is often used for such major pipeline updates, but RNS is the broader regulatory fallback. However, the document structure and content (major clinical data release) often map closely to what is released alongside or instead of a formal Earnings Release in the biotech sector. Since it is a comprehensive announcement of a major development, and not just a brief notice of a report being available (which would be RPA), I will classify it as an Earnings Release (ER) as it communicates the 'results' of a key operational area (R&D pipeline). If ER is too narrow, RNS is the alternative. Given the detailed nature of the results, ER is a strong candidate, but RNS covers general regulatory announcements well. Let's re-evaluate against the definitions. It is not a 10-K, AR, IR, or CT. It is a major announcement of results. ER is for 'initial announcement of periodical financial results (key highlights only)'. This is a clinical result announcement, not a financial one. Therefore, RNS (General regulatory announcements and fallback category) is the most appropriate fit for a major, non-standard financial/regulatory announcement like this clinical trial readout.
2023-06-30 French
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Regulatory Filings Classification · 99% confidence The document is a press release dated June 30, 2023, announcing positive topline data from the Phase III ELATIVE® trial for elafibranor in treating primary biliary cholangitis (PBC). It details the trial results (meeting primary and secondary endpoints), safety profile, and explicitly states that Ipsen 'intends to submit regulatory applications' and 'plans to move forward with regulatory submissions to the U.S. Food and Drug Administration and the European Medicines Agency.' It also announces a conference call to discuss these results. This content is characteristic of an initial announcement of key clinical trial results, which aligns best with the 'Earnings Release' (ER) category if it were financial results, but since it is clinical/pipeline news, it is most closely related to an 'Investor Presentation' (IP) or a general 'Regulatory Filing' (RNS). However, given the structure—a formal announcement of major positive data and immediate next steps regarding regulatory submission—it functions as a significant corporate update intended for investors. Since it is not a full financial report (10-K/IR) or a transcript (CT), and it's more detailed than a simple 'Report Publication Announcement' (RPA), it fits best as an Investor Presentation (IP) which often includes such detailed press releases about trial milestones, or as a general Regulatory Filing (RNS). Given the focus on trial results and future regulatory strategy, 'Investor Presentation' (IP) is a strong fit as these press releases often precede or accompany investor presentations. However, the document itself is a press release announcing results and future regulatory intent, which often falls under the broader 'Regulatory Filings' (RNS) if a more specific category isn't available. Since the document is substantial (18k chars) and contains detailed scientific and corporate information, it is more than just a brief announcement. Comparing the options, 'Investor Presentation' (IP) covers detailed strategic and clinical updates aimed at investors. If this were purely a regulatory submission document, it would be different. Since it is a public announcement of data that will be discussed in a call, IP is appropriate. If we consider the context of major clinical trial success announcements, they are often bundled with Investor Presentations or used as the basis for them. I will classify it as an Investor Presentation (IP) due to the depth of clinical data and forward-looking strategy shared with the market.
2023-06-30 English
GENFIT annonce de nouvelles données au congrès 2023 de l’European Association for the Study of the Liver (EASL)
Regulatory Filings Classification · 94% confidence The document is a press release dated June 7, 2023, announcing that GENFIT will present new preclinical and clinical data (posters and presentations) at the European Association for the Study of the Liver (EASL) congress in Vienna. It details the titles of the posters, the sessions, and mentions an Investigator Meeting. The text is structured as a formal corporate announcement detailing upcoming scientific disclosures, rather than being the full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing like a proxy statement or earnings release. Since it is an announcement about scientific data presentation at a conference, it most closely aligns with a general corporate update or announcement. Given the options, it is a general announcement that doesn't fit the specific financial or governance codes. Therefore, the most appropriate fallback category is Regulatory Filings (RNS), as it is a public disclosure of material information, although it is not a standard SEC/AMF filing type listed. However, looking closely at the content, it is an announcement of scientific/clinical progress, which often falls under Investor Relations material. Since there is no specific 'Clinical Update' or 'Scientific Presentation Announcement' code, and it is not a short notice about a report being available (RPA), RNS serves as the best general disclosure category.
2023-06-07 French
GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023
Regulatory Filings Classification · 99% confidence The document is a press release dated June 7, 2023, announcing that GENFIT will present new data at the European Association for the Study of the Liver (EASL) Congress 2023. It details the titles, poster numbers, and session times for three specific poster presentations related to their research (NTZ in ACLF and NIS2+™ in NASH). This type of announcement, detailing upcoming scientific presentations or data releases, is characteristic of an Investor Presentation (IP) or a general announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT), and it is specifically focused on presenting scientific/clinical data updates to investors and the public, 'Investor Presentation' (IP) is the most fitting category, although it functions as an announcement of data to be presented, which sometimes overlaps with ER/RPA. However, given the detailed breakdown of scientific posters and the context of a biopharma company presenting research findings, IP is the best fit among the provided options for content focused on clinical/scientific updates intended for investors. It is not a Report Publication Announcement (RPA) because it announces future presentations, not the publication of a formal report itself.
2023-06-07 English
GENFIT renforce sa franchise ACLF avec un troisième composé de stade clinique
Regulatory Filings Classification · 100% confidence The document is a press release dated May 31, 2023, announcing a licensing agreement between GENFIT and Seal Rock Therapeutics regarding the SRT-015 compound for Acute on Chronic Liver Failure (ACLF). It details clinical pipeline updates (VS-01, NTZ), market size estimates, and includes standard forward-looking statements and company information. This type of announcement, focusing on a significant business development (licensing deal) and pipeline progress, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a detailed announcement of a major event rather than just the release of periodic financial results (which would be ER), and it is not a transcript (CT), a formal annual report (10-K), or a proxy statement (DEF 14A), it fits best as a general corporate announcement. Given the options, 'Earnings Release' (ER) is often used for significant corporate news releases, but 'Regulatory Filings' (RNS) serves as a broad category for non-standard, material corporate announcements that aren't explicitly covered elsewhere. However, the content is highly focused on business development and clinical progress, which often accompanies or substitutes for an ER in biotech/pharma. Since it is a formal press release announcing a material event (licensing deal and pipeline status), and it is not explicitly a 'Report Publication Announcement' (RPA) as it contains the substance, it is most closely aligned with an 'Earnings Release' (ER) in function as a primary communication of corporate status, or potentially 'Regulatory Filings' (RNS) if it were a mandatory filing. Given the nature of the announcement (licensing, pipeline updates), ER is a strong candidate, but since it's not explicitly quarterly results, I will lean towards the general material announcement category, RNS, as it is a press release detailing corporate actions. Re-evaluating the definitions: ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not primarily about quarterly results. It is a business development announcement. Since there is no specific 'Business Development' code, and it's a formal announcement, RNS (Regulatory Filings/General regulatory announcements) is the most appropriate fallback for material, non-standard corporate news.
2023-05-31 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.